Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804462 | 0.80 | MAPT (0.48) | MAPTRAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10850245 | 0.78 | MAPT (0.47) | MAPTRAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9739707 | 0.78 | KMT2A (0.47) | MAPTRAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17975326 | 0.78 | GAA (0.52) | MAPTRAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11463095 | 0.77 | CYP1A2 (0.70) | MAPTRAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27673535 | 0.77 | RAB9A (0.46) | MAPTRAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10634673 | 0.75 | MAPT (0.49) | MAPTRAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10853491 | 0.75 | MAPT (0.44) | MAPTRAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3867453 | 0.74 | MAPT (0.62) | MAPTRAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6182511 | 0.74 | KMT2A (0.47) | MAPTRAB9ACYP2C9KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445677-B2 | Substituted pyrimidyl guanidine derivatives having anticancer activity | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100160313-A1 | DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160313-A1 | DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE | ABCG2, NQO2, TOP1 | MAPT 4028/4885RAB9A 1979/4885CYP1A2 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.